Protein Therapeutics Pipeline Analysis 2018

Protein is a large biomolecule, composed of one or more long chains of amino acids, known as polypeptide. Proteins play an important role in metabolic reactions, transporting molecules, and DNA replication. Proteins differ from one another in their sequence of amino acids.

The stabilization of protein involves its folding as well as mis-folding, which require hydrogen bonds, disulphide bonds, and covalent bonds. Human parathyroid hormone protein is an important regulator of calcium homeostasis.

Get the detailed analysis at: www.pharmaproff.com/report/protein-therapeutics

The protein consisting of 84 amino acids target cells in the bone and kidney tubuli. The pharmacological action of protein therapeutics includes decreased serum phosphate level, increased serum calcium level, and decreased urinary excretion of calcium and phosphate.

Rhein-Minapharm Inc. is in the process of developing recombinant elafin protein as an immunomodulator for the treatment of inflammatory disease. Ventria Bioscience Inc. is in the process of developing VEN120 for the treatment of inflammatory bowel disease. Protalix Biotherapeutics Ltd. is formulating pegunigalsidase alfa as an alpha-galactosidase replacement for the treatment of Fabry disease. Some of the companies with pipeline of protein therapeutics are Adello Biologics LLC, Protalix Ltd., and XL-protein GmbH among others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.